PR Newswire Clinical TrialsOriginal article
CluePoints and Tufts CSDD Publish Peer-Reviewed Evidence Quantifying the Financial Value of RBQM
Positive
AI Analysis
Summary
CluePoints and Tufts CSDD published peer-reviewed research demonstrating that risk-based quality management (RBQM) in clinical trials can achieve up to 23x ROI and reduce phase duration by 19%, providing quantitative business justification for implementing risk-based oversight in drug development.
Importance:3/10
Sentiment:
0.60
risk-based quality managementRBQMclinical trial efficiencypeer-reviewed researchtrial optimization
Read the original article
Published by PR Newswire Clinical Trials on July 7, 2026 1:00 PM